To understand the activity and mechanism of action of NKTR-214 in T-cell-based immunotherapy of cancer, we studied its use in preclinical models of PD-1 and CTLA-4 CPI therapy and in antigen-specific vaccination as well as in patient samples. This evidence concerns the gene NKTR and cancer.